Chronic progressive multiple sclerosis

This trial tests a therapy called CTX112 in adults with severe neurologic autoimmune diseases, including progressive multiple sclerosis, neuromyelitis optica, and stiff-person syndrome. CTX112 uses donor T cells edited with CRISPR to target and deplete B cells, which are thought …

Researchers are testing a one-time CAR-T cell therapy called C-CAR168 in adults with progressive multiple sclerosis that has not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to target two proteins, and is given as a single intravenou…

This trial is testing an experimental therapy called CTA313, which uses engineered immune cells (CAR T cells) to potentially reset the immune system in people with active autoimmune diseases. The study will include adults aged 18 to 75 with systemic lupus erythematosus, progressi…

This study tests an experimental drug called remibrutinib in 20 people with relapsing or progressive multiple sclerosis (MS). Participants take the drug twice daily for 2 years and undergo powerful 7T MRI scans to measure changes in brain volume, lesions, and tissue health. The g…

This phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug…

This trial tests an experimental therapy called SYS6020 for people with relapsing or progressive multiple sclerosis that hasn't responded well to standard treatments. SYS6020 uses a patient's own immune cells, engineered to target and potentially reduce harmful B cells involved i…

This early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the rig…

This phase IIa trial tests a personalized cell therapy for people with progressive multiple sclerosis (MS). The treatment uses the patient's own immune cells, turned into 'tolerogenic dendritic cells' that are designed to calm the immune system and stop it from attacking the nerv…

This study tests whether breathing low-oxygen air for short periods right before walking training helps people with multiple sclerosis walk better and farther. Thirty-five participants will receive either the low-oxygen breathing or a sham (placebo) version, followed by treadmill…

This early-stage trial tests whether a combination of two drugs, dasatinib and quercetin, can safely remove aged, damaged cells that may contribute to inflammation and nerve damage in people with secondary progressive multiple sclerosis (MS). The study enrolls 30 adults aged 50-8…

This study will check if three substances in the blood (GFAP, NfL, and VEGF) are linked to how quickly disability gets worse in people with progressive multiple sclerosis. Researchers will measure these markers and compare them to standard tests of disability and thinking. The go…

This study will collect health data and samples from 100 people with multiple sclerosis over several years. Researchers will use artificial intelligence and data science to find patterns that could help predict how the disease will progress. The goal is to eventually personalize …